Table 2.
Mortality odds ratio (95% CI) | p value | |
---|---|---|
Model 1 | 0.44 (0.29–0.67) | < 0.001 |
Model 2 | 0.45 (0.30–0.68) | < 0.001 |
Model 3 | 0.39 (0.24–0.64) | < 0.001 |
Model 3 with a statistical interaction term for HCQ and azithromycin | ||
1 Main effect HCQ | 0.56(0.34–0.92) | 0.022 |
2 Main effect azithromycin | 0.53(0.19–1.50) | 0.233 |
3 Interaction (1 and 2) | 1.11(0.38–3.29) | 0.846 |
Model 4 | 0.39 (0.24–0.64) | < 0.001 |
Model 1 Adjusted for age and gender
Model 2 Adjusted for age, gender, temperature > 37 °C, and saturation of oxygen < 90%
Model 3 Adjusted for age, gender, temperature > 37 °C, and saturation of oxygen < 90% treatment with azithromycin, steroids, heparin, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir
Model 4 Adjusted for age, gender, temperature > 37 °C, and saturation of oxygen < 90% treatment with azithromycin, steroids, heparin, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, and date of admission